Literature DB >> 19943130

MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy.

Sven Gunia1, Matthias May, Stefan Koch, Manfred Dietel, Andreas Erbersdobler.   

Abstract

The behavior of Incidental prostate cancer (IPC) cannot be reliably predicted by means of conventional histomorphology. MUC1 (episialin) expression has been linked to poor outcome in peripheral prostate cancer (PC). We aimed to determine the so far neglected prognostic role of MUC1 expression in IPC which most commonly represents transition zone cancer. Using Tissue microarray (TMA), we assessed the association between MUC1 expression recorded in transurethral resection specimens of the prostate (TURP chips) and histopathologic outcome parameters (Gleason scores and histologic staging) performed on the subsequent radical prostatectomies (RPs) in a study cohort of 54 patients. Due to tissue loss during arraying and sectioning, a total of 44 (81.5%) tumor samples remained available for immunostaining which was dichotomized by two independent clinical pathologists as being absent or present. MUC1 expression was present in 7 (15.9%) of the 44 IPC immunohistochemically investigated with a striking over-representation in high stage tumors, and was significantly correlated with histopathologic staging (ρ = 0.4; p = 0.02) and Gleason scores (ρ = 0.3; p = 0.03) performed on the corresponding RPs. These data were confirmed by means of the McNemar test (staging: p = 0.01; grading: p = 0.04). Our findings suggest that MUC1 might become a valuable adjunct to enable individual prognostic ramification prior to radical surgery in prostate cancer histologically detected in TURP chips. This interesting observation clearly awaits validation by larger studies surveying clinical follow-up data.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19943130     DOI: 10.1007/s12253-009-9231-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  15 in total

1.  Outcome of radical prostatectomy for incidental carcinoma of the prostate.

Authors:  Sebastian Melchior; Boris Hadaschik; Sebastian Thüroff; Christian Thomas; Rolf Gillitzer; Joachim Thüroff
Journal:  BJU Int       Date:  2008-12-08       Impact factor: 5.588

2.  Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification.

Authors:  C A Sheldon; R D Williams; E E Fraley
Journal:  J Urol       Date:  1980-11       Impact factor: 7.450

3.  Influence of MUC1 genetic variation on prostate cancer risk and survival.

Authors:  Rona J Strawbridge; Monica Nister; Kerstin Brismar; Chunde Li; Sara Lindström
Journal:  Eur J Hum Genet       Date:  2008-07-16       Impact factor: 4.246

4.  The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parameters.

Authors:  Carl Morrison; Kambiz Merati; William L Marsh; Lindsey De Lott; David E Cohn; Gregory Young; Wendy L Frankel
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-12

Review 5.  Colorectal mucin histochemistry in health and disease: a critical review.

Authors:  J R Jass; A M Roberton
Journal:  Pathol Int       Date:  1994-07       Impact factor: 2.534

Review 6.  Incidental carcinoma of the prostate.

Authors:  G van Andel; R Vleeming; K Kurth; T M de Reijke
Journal:  Semin Surg Oncol       Date:  1995 Jan-Feb

Review 7.  Advances of MUC1 as a target for breast cancer immunotherapy.

Authors:  E Yang; X F Hu; P X Xing
Journal:  Histol Histopathol       Date:  2007-08       Impact factor: 2.303

Review 8.  MUC1 is a promising therapeutic target for prostate cancer therapy.

Authors:  Y Li; P J Cozzi
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

9.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies.

Authors:  Sven Gunia; Stefan Koch; Matthias May; Manfred Dietel; Andreas Erbersdobler
Journal:  Virchows Arch       Date:  2009-03-20       Impact factor: 4.064

View more
  2 in total

1.  MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.

Authors:  Okyaz Eminaga; Wei Wei; Sarah J Hawley; Heidi Auman; Lisa F Newcomb; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin E Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Jesse K McKenney; Ziding Feng; Ladan Fazli; James D Brooks
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

2.  The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1.

Authors:  Annika Fendler; Monika Jung; Carsten Stephan; Andreas Erbersdobler; Klaus Jung; George M Yousef
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.